AOTMiT: Transparency Council on breast cancer, ADHD and phenylketonuria, among others

Agenda:

1. Preparation of a position paper on the qualification of the benefit:
   "Program for early detection of lung cancer in persons with an increased, defined risk of the disease, by means of low-dose computed tomography (NDTK)"
   as a guaranteed benefit.
2. Preparation of a position paper on the evaluation of the drug PKU GMPro Mix In
   for the indication: dietary management of patients with phenylketonuria over 3 years of age.
3. Preparation of a position paper on the evaluation of the drug Trodelva (sacituzumabum govitecanum)
   under drug program B.9.FM. "Treatment of patients with breast cancer (ICD-10: C50)".
4. Preparation of a position paper on the evaluation of the drug Tecartus (brexucabtagene autoleucel)
   within the framework of the drug program B.12.FM. "Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)".
5. Preparation of a position paper on the evaluation of the drug Buccolam (midazolamum)
   for the indication: prolonged, acute seizures in adults.
6. Preparation of a position paper on investigating the appropriateness of issuing reimbursement approvals for the medicinal product Intuniv (guanfacinum)
   for the indications:
   
   • Attention deficit hyperactivity disorder(ADHD),
   • Tourette's syndrome,
   • Tourette syndrome with co-morbid ADHD.

Source: AOTMiT